Literature DB >> 18613071

Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.

Qi-Shi Du1, Ri-Bo Huang, Yu-Tuo Wei, Zong-Wen Pang, Li-Qin Du, Kuo-Chen Chou.   

Abstract

In cooperation with the fragment-based design a new drug design method, the so-called "fragment-based quantitative structure-activity relationship" (FB-QSAR) is proposed. The essence of the new method is that the molecular framework in a family of drug candidates are divided into several fragments according to their substitutes being investigated. The bioactivities of molecules are correlated with the physicochemical properties of the molecular fragments through two sets of coefficients in the linear free energy equations. One coefficient set is for the physicochemical properties and the other for the weight factors of the molecular fragments. Meanwhile, an iterative double least square (IDLS) technique is developed to solve the two sets of coefficients in a training data set alternately and iteratively. The IDLS technique is a feedback procedure with machine learning ability. The standard Two-dimensional quantitative structure-activity relationship (2D-QSAR) is a special case, in the FB-QSAR, when the whole molecule is treated as one entity. The FB-QSAR approach can remarkably enhance the predictive power and provide more structural insights into rational drug design. As an example, the FB-QSAR is applied to build a predictive model of neuraminidase inhibitors for drug development against H5N1 influenza virus. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18613071     DOI: 10.1002/jcc.21056

Source DB:  PubMed          Journal:  J Comput Chem        ISSN: 0192-8651            Impact factor:   3.376


  17 in total

1.  QSAR classification of metabolic activation of chemicals into covalently reactive species.

Authors:  Chin Yee Liew; Chuen Pan; Andre Tan; Ke Xin Magneline Ang; Chun Wei Yap
Journal:  Mol Divers       Date:  2012-02-28       Impact factor: 2.943

2.  Consensus QSAR model for identifying novel H5N1 inhibitors.

Authors:  Nitin Sharma; Chun Wei Yap
Journal:  Mol Divers       Date:  2012-07-21       Impact factor: 2.943

3.  Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies.

Authors:  Rajesh B Patil; Euzebio G Barbosa; Jaiprakash N Sangshetti; Vishal P Zambre; Sanjay D Sawant
Journal:  Mol Divers       Date:  2018-03-13       Impact factor: 2.943

4.  Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions.

Authors:  Kyaw-Zeyar Myint; Lirong Wang; Qin Tong; Xiang-Qun Xie
Journal:  Mol Pharm       Date:  2012-08-31       Impact factor: 4.939

5.  Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.

Authors:  Jiansong Fang; Ranyao Yang; Li Gao; Shengqian Yang; Xiaocong Pang; Chao Li; Yangyang He; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2014-12-16       Impact factor: 2.943

6.  Meta-heuristics on quantitative structure-activity relationships: study on polychlorinated biphenyls.

Authors:  Lorentz Jäntschi; Sorana D Bolboacă; Radu E Sestraş
Journal:  J Mol Model       Date:  2009-07-17       Impact factor: 1.810

Review 7.  Recent advances in fragment-based QSAR and multi-dimensional QSAR methods.

Authors:  Kyaw Zeyar Myint; Xiang-Qun Xie
Journal:  Int J Mol Sci       Date:  2010-10-08       Impact factor: 5.923

8.  3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors.

Authors:  Mahreen Arooj; Sundarapandian Thangapandian; Shalini John; Swan Hwang; Jong Keun Park; Keun Woo Lee
Journal:  Int J Mol Sci       Date:  2011-12-12       Impact factor: 5.923

9.  Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.

Authors:  Ying Ma; Shu-Qing Wang; Wei-Ren Xu; Run-Ling Wang; Kuo-Chen Chou
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

10.  Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.

Authors:  Lei Liu; Ying Ma; Run-Ling Wang; Wei-Ren Xu; Shu-Qing Wang; Kuo-Chen Chou
Journal:  Drug Des Devel Ther       Date:  2013-04-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.